BMS Discovery Biotherapeutics

Bristol Myers Squibb (BMS) is a premier global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines for patients with serious diseases. The company's Discovery Biotherapeutics division is a specialized research engine focused on the early-stage development of complex biologics, including monoclonal and bispecific antibodies. BMS maintains a dominant position in immuno-oncology, hematology, and cardiovascular medicine, supported by a portfolio of high-impact therapies such as Opdivo and Eliquis. Through strategic acquisitions like Celgene and Karuna Therapeutics, the company has expanded its capabilities into cell therapy and neuroscience. BMS continues to advance its pipeline using cutting-edge technologies like targeted protein degradation and next-generation CAR-T platforms.